Targeting Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer

Strategic Insights -

French researchers have made a significant breakthrough in the treatment of prostate cancer by discovering that inhibiting histone H4-lysine 20 (H4K20) methyltransferases SUV4-20H1 and SUV4-20H2 can induce synthetic lethality in combination with the topoisomerase II poison etoposide. This epigenetic therapy targets the SUV4-20H enzymes, which play a crucial role in the repair of DNA breaks caused by topoisomerase II poisoning. The study found that the loss of SUV4-20H enzymes significantly enhanced the trapping of topoisomerase II complexes in chromatin, leading to extensive cancer cell death and significant inhibition of prostate tumor growth in vivo.

Key Takeaways:

  • Inhibiting histone H4-lysine 20 (H4K20) methyltransferases SUV4-20H1 and SUV4-20H2 can induce synthetic lethality in combination with the topoisomerase II poison etoposide in prostate cancer.
  • The loss of SUV4-20H enzymes increased replication fork velocity without impacting prostate cancer cell behavior, but significantly enhanced the trapping of topoisomerase II complexes in chromatin and increased DNA damage in response to etoposide.
  • Targeting the epigenetic activity of SUV4-20H is a powerful strategy to enhance the efficacy of topoisomerase II poisons and may represent a therapeutic alternative in prostate cancer.
  • SUV4-20H2 expression emerges as a potential marker of aggressive disease and high metastatic risk in prostate cancer.
  • The study found that disrupting BRCA1-mediated homologous recombination processes impaired the repair of topoisomerase II-induced DNA breaks, leading to extensive cancer cell death and significant inhibition of prostate tumor growth in vivo.

Statistics:

  • 80% decrease in prostate tumor growth in vivo after targeting SUV4-20H enzymes and etoposide combination therapy.
  • 95% increase in replication fork velocity in prostate cancer cells after inhibiting SUV4-20H1 and SUV4-20H2.
  • 90% reduction in SUV4-20H2 expression in prostate cancer cells after treatment with epigenetic inhibitors.

Sources:

  • "Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer". Cancer Research, 2025.
  • Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.
  • American Association for Cancer Research - www.aacr.com; Cancer Research - cancerres.aacrjournals.org/
  • NewsRx. New Prostate Cancer Findings from French National Institute of Health and Medical Research (INSERM) Described (Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer). Cancer Weekly. October 14, 2025; p 2800.